Sigyn Therapeutics CEO Jim Joyce outlined the therapeutic potential of the company's CardioDialysis technology while addressing strategic challenges in a shareholder update. The therapy targets cholesterol-transporting lipoproteins and inflammatory molecules that drive cardiovascular disease, the leading cause of death worldwide, and could address sepsis, the leading cause of in-hospital mortality. CardioDialysis is designed for use on existing dialysis machines at more than 7,500 U.S. clinics, potentially overcoming limitations of current lipoprotein apheresis available at fewer than 60 specialized centers.
The technology also shows promise for traumatic brain injury and other disorders where reducing systemic inflammation could aid recovery. Joyce noted that while lipoprotein apheresis devices reduce major adverse cardiovascular events more effectively than drugs, CardioDialysis offers broader targeting of both lipoproteins and inflammatory mediators. For sepsis treatment, Joyce referenced the PMX hemoadsorption device being developed by Spectral Medical, a company with approximately $300 million market value, while noting CardioDialysis has been validated to reduce sepsis-inducing toxins and inflammatory mediators.
Despite therapeutic advancements, Joyce acknowledged challenges with the company's OTC trading status and failed Nasdaq uplisting attempt. The financing effort was complicated by regulatory requirements where Nasdaq wanted to review investors before SEC deemed the registration statement effective, while SEC wanted contingent Nasdaq approval first. This created what Joyce described as a catch-22 situation that ultimately led to withdrawing the registration statement. The share price and exchange limitations have impacted the company's ability to raise capital without harming shareholder value.
Joyce highlighted strategies to move forward with reduced shareholder dilution, including potential asset sales and a merger with a Nasdaq-listed company at risk of not meeting the forthcoming $5 million minimum market value requirement. He encouraged shareholders to review his January 15th update detailing these approaches available at https://www.sigyntherapeutics.com/investors/news-events/press-releases/detail/118/sigyn-therapeutics-issues-shareholder-update-highlighting. The company reported 2,330,042 shares outstanding as of March 11, 2026.
Joyce previously founded Aethlon Medical, where he oversaw development of the Hemopurifier that received multiple FDA Breakthrough Device designations and was named a TIME magazine Top 25 Invention. That company achieved Nasdaq listing with peak market value of approximately $200 million. At Sigyn, the CardioDialysis technology represents what Joyce describes as one of the most significant opportunities in healthcare, targeting multiple life-threatening conditions through a single therapeutic approach while leveraging existing dialysis infrastructure.
